Myota, a London-based provider of clinically validated prebiotic fibre blends, has raised $4.5M in Series A funding led by PeakBridge. The blends deliver short-chain fatty acids that support metabolic, heart, brain, immune, and gut health while addressing fibre deficiency across diverse microbiomes. The capital will expand its DTC platform and scale B2B ingredient partnerships across Europe and the US.
Fibre Gap Converges With GLP-1 Demand
The timing aligns with surging interest in fibre as both a standalone wellness driver and a companion to GLP-1 weight-loss drugs. ZOE raised $15M Series B+ in July 2024, while Supergut secured $22M Series B in February 2025. Myota's multi-fibre approach targets the gap that single-source or test-dependent competitors leave unaddressed.
95% Fibre Deficiency Drives Opportunity
Ninety-five percent of Brits and Americans fall short on daily fibre intake. Myota's products have demonstrated 28% reductions in blood sugar spikes, 61% improvements in insulin sensitivity, and 80% reductions in bloating in gold-standard trials. Most fibre supplements fail sensitive stomachs; Myota's low-FODMAP certification opens access to IBS sufferers excluded from standard options.
Universal Efficacy Without Testing
Myota formulates blends that reliably generate beneficial short-chain fatty acids across varied gut microbiomes rather than requiring expensive personalization tests. The flavourless powder integrates into existing meals and drinks. This differs from ZOE and Viome's diagnostics-first model and from Supergut's meal-replacement positioning.
"We can measure how an individual's gut bacteria ferment different fibres, and we use that to build blends that produce short-chain fatty acids reliably across very different microbiomes." — Thomas Gurry, CSO
PeakBridge Extends Five-Year Thesis
PeakBridge led the round, continuing support it began at seed stage. The investor first identified fibre as a nutrition pillar five years ago. The new capital backs Myota's shift from pure DTC toward B2B ingredient supply for food manufacturers, a route described as more capital-efficient for scale.
Prebiotic Market Expands Rapidly
The prebiotic fibre market is projected to grow from $7.1B in 2025 to $13.1B by 2035 at 6.3% CAGR, while the broader gut health market exceeds $71B in 2026 and is expected to surpass $105B by 2030. per Grand View Research and per Global Market Insights. Competitors include Viome ($175M+ raised) and ResBiotic ($14.5M total, including $8M Series A in September 2025).
MIT-Trained Founders Anchor Science
Co-founders Dr Thomas Gurry (PhD MIT) and Dr Caitlin Hall (PhD gut microbiology) bring deep academic credentials from MIT and Cambridge research partnerships. Half the team holds PhDs. The company has completed seven clinical trials with more underway, including NHS-approved studies on the gut-brain axis.
Team Expansion and US Push Ahead
Post-funding plans include hiring across DTC, B2B sales, and R&D plus geographic expansion of ingredient partnerships into the United States alongside continued European growth.